Diabetic kidney disease: Are the reported associations with single-nucleotide polymorphisms disease-specific?

doi:10.4239/wjd.v12.i10.1765

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 10

This Article

Academic Content and Language Evaluation of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2941)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-4) series.

Item

Count

PDF

194

WORD

146

HTML

1556

Tables (1-4)

155

Sum=2051

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

284

Download

606

Sum=890

Oct 15, 2021 (publication date) through May 12, 2024

Times Cited of This Article

Times Cited (1)

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Control Study

World J Diabetes. Oct 15, 2021; 12(10): 1765-1777
Published online Oct 15, 2021. doi: 10.4239/wjd.v12.i10.1765

Table 1 Study and control group characteristics

	DKD (n = 117)	NDKD (n = 110)	P value
Age (yr)	68.94 (7.90)	69.87 (10.86)	0.46
Male sex (%)	57 (48.72)	66 (60.00)	0.088
Time-to-dialysis (yr)	5.25 (5.16)	6.23 (6.09)	0.20
Rapid progression of CKD (TTD ≤ 3 mo) (%)	6 (5.13)	6 (5.45)	0.91
Fast progression of CKD (TTD ≤ 1 yr) (%)	29 (24.79)	21 (19.09)	0.30
Slow progression of CKD (TTD > 5 yr) (%)	37 (31.62)	43 (39.09)	0.24
BMI (kg/m²)	30.21 (16.35)	26.01 (5.15)	0.01
Smoking ever (%)	52 (44.44)	58 (53.21)¹	0.19
Preserved diuresis (%)	97 (82.91)	85 (77.27)	0.29
24 h diuresis > 500 mL (%)	49 (41.88)	46(41.82)	0.99
Hypertension (%)	114 (97.44)	102 (92.73)	0.099
ACE-I (%)	50 (43.48)²	39 (39.39)⁴	0.54
ARB (%)	17 (14.78)²	12 (11.76)⁵	0.51
Beta-blockers (%)	89 (76.72)³	91 (89.22)⁵	0.015
Statins (%)	76 (66.09)²	57 (58.16)⁶	0.23

¹Data available for 109 patients.

²Data available for 115 patients.

³Data available for 116 patients.

⁴Data available for 99 patients.

⁵Data available for 102 patients.

⁶Data available for 98 patients.

Significant differences are highlighted in bold. ACE-I: Angiotensin-converting-enzyme inhibitors; ARB: Angiotensin II receptor blockers; BMI: Body mass index; CKD: Chronic kidney disease; DKD: Diabetic kidney disease; NDN: Non-diabetic kidney disease; TTD: Time-to-dialysis (time between the diagnosis of chronic kidney disease and start of hemodialysis).

Table 2 Single-nucleotide polymorphisms’ associations with diabetic kidney disease

SNP	DKD		NDKD		OR	P value
SNP	E	N	E	N	OR	P value
rs1617640	123	111	119	101	0.94 (0.65-1.36)	0.78
rs841853	84	150	60	160	1.49 (1.00-2.23)	0.048
rs1800783	67	167	69	151	0.88 (0.59-1.31)	0.53
rs1531343	23	211	17	203	1.30 (0.68-2.51)	0.43
rs1800470	91	143	93	127	0.87 (0.60-1.26)	0.46
rs759853	94	140	74	146	1.32 (0.90-1.94)	0.15
rs1801282	40	194	35	185	1.06 (0.66-1.79)	0.73
rs13293564	104	130	91	129	1.13 (0.78-1.65)	0.51
rs2268388	29	205	32	188	0.83 (0.48-1.43)	0.50

DKD: Diabetic kidney disease; E: Effect allele; NDKD: Non-diabetic kidney disease; N: Non-effect allele; OR: Odds ratio; SNP: Single nucleotide polymorphism.

Table 3 Associations between genetic risk score and different parameters in diabetic kidney disease and non-diabetic kidney disease patients

Parameter	DKD + NDKD, n = 227		DKD, n = 117		NDKD¹, n = 91
Parameter	GRS, mean ± SD	P value	GRS, mean ± SD	P value	GRS, mean ± SD	P value
Rapid progression (TTD ≤ 3 mo vs > 3 mo)	0.602 ± 0.233 vs 0.603 ± 0.258	0.99	0.518 ± 0.273 vs 0.620 ± 0.260	0.34	0.687 ± 0.167 vs 0.574 ± 0.248	0.27
Fast progression (TTD ≤ 1 yr vs > 1 yr)	0.592 ± 0.246 vs 0.606 ± 0.260	0.75	0.600 ± 0.229 vs 0.620 ± 0.270	0.71	0.522 ± 0.253 vs 0.593 ± 0.242	0.30
Slow progression (TTD > 5 yr vs ≤ 5 yr)	0.596 ± 0.256 vs 0.607 ± 0.258	0.77	0.629 ± 0.286 vs 0.608 ± 0.249	0.69	0.583 ± 0.230 vs 0.580 ± 0.257	0.96
Diuresis (preserved diuresis vs no diuresis)	0.614 ± 0.260 vs 0.557 ± 0.239	0.18	0.622 ± 0.265 vs 0.578 ± 0.235	0.49	0.605 ± 0.244 vs 0.503 ± 0.235	0.09
24h diuresis > 500 mL (> 500 mL vs ≤ 500 mL)	0.630 ± 0.244 vs 0.583 ± 0.265	0.17	0.621 ± 0.258 vs 0.611 ± 0.263	0.83	0.643 ± 0.220 vs 0.535 ± 0.253	0.035
Male sex (males vs females)	0.639 ± 0.265 vs 0.591 ± 0.255	0.31	0.617 ± 0.263 vs 0.586 ± 0.249	0.37	0.589 ± 0.251 vs 0.568 ± 0.235	0.70

¹Cases with complex pathogenesis excluded from analysis.

DKD: Diabetic kidney disease; NDKD: Non-diabetic kidney disease; GRS: Genetic risk score; TTD: Time-to-dialysis (time between the diagnosis of chronic kidney disease and start of hemodialysis). Significant differences are highlighted in bold.

Table 4 The distribution of genetic risk score in particular end-stage kidney disease subgroups

Group	GRS	P value	Post-hoc analysis
Classification: (1) GD, (2) TID, (3) VD, (4) CCD, (5) CP
		0.09	GD vs TID	P = 0.014
			GD vs VD	P = 0.12
GD (n = 146)	0.628 ± 0.256		GD vs CCD	P = 0.61
TID (n = 16)	0.461 ± 0.218		GD vs CP	P = 0.97
VD (n = 33)	0.551 ± 0.269		TID vs VD	P = 0.24
CCD (n = 13)	0.590 ± 0.138		TID vs CCD	P = 0.18
CP (n = 19)	0.629 ± 0.298		TID vs CP	P = 0.051
			VD vs CCD	P = 0.64
			VD vs CP	P = 0.29
			CCD vs CP	P = 0.66
Classification: (1) GD, (2) TID+VD+CCD, (3) CP
GD (n = 146)	0.628 ± 0.256	0.055	GD vs TID+VD+CCD	P = 0.018
TID+VD+CCD (n = 62)	0.536 ± 0.235		GD vs CP	P = 0.97
CP (n = 19)	0.629 ± 0.298		TID+VD+CCD vs CP	P = 0.16
Classification: (1) GD, (2) TID+VD+CCD+CP
GD	0.628 ± 0.256	0.051	N/A
TID+VD+CCD+CP	0.558 ± 0.253	0.051	N/A

Genetic risk score is presented as mean ± SD. GRS: Genetic risk score; GD: Glomerular disease; TID: Tubulointerstitial disease; VD: Vascular diseases; CCD: Cystic and congenital disease; CP: Complex pathogenesis; N/A: Not applicable.

Citation: Saracyn M, Kisiel B, Franaszczyk M, Brodowska-Kania D, Żmudzki W, Małecki R, Niemczyk L, Dyrla P, Kamiński G, Płoski R, Niemczyk S. Diabetic kidney disease: Are the reported associations with single-nucleotide polymorphisms disease-specific? World J Diabetes 2021; 12(10): 1765-1777
URL: https://www.wjgnet.com/1948-9358/full/v12/i10/1765.htm
DOI: https://dx.doi.org/10.4239/wjd.v12.i10.1765